Stage III Breast Cancer Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0031775 (Stage III Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02971761Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerTreatment